Global Biopharmaceutical Manufacturing Market Report 2017-2021



IMARC Group’s latest report titled “Global Biopharmaceutical Manufacturing Market Report 2017-2021” provides a detailed analysis on the global biopharmaceutical manufacturing market. Biopharmaceuticals represent one of the most elegant and sophisticated achievements of modern science. Compared to small molecules which are synthesized chemically, biopharmaceuticals or biologics are manufactured from biological sources and have proved to be efficacious in the treatment of various chronic and other rare diseases for which there are no available treatments. The production of biopharmaceuticals reliably at an industrial scale, however, involves highly complex manufacturing capabilities. This involves genetically engineered living cells that must be frozen for storage, thawed without causing any damage, and made to grow in the unusual environment of a reaction vessel. The molecules once produced must then be segregated from the living cells that produced them and the media in which they were made, all without damaging their complex, fragile structures. Such production facilities are also notably more expensive and involve longer time lines to build compared to small molecule drugs. These facilities are also significantly costlier to run, involving long process durations, low yields, costly raw materials, and require a team of highly skilled experts to operate them.

biopharmaceuticals manufacturing market

The efficacy and safety of biopharmaceuticals, coupled with their ability to address previously untreatable conditions, allows healthcare companies to command higher prices and margins for these drugs. Driven by their numerous advantages over conventional drugs, biopharmaceuticals today represent a big opportunity and represent more than 20% of the total global pharmaceutical sales. The current annual growth rate of biopharmaceuticals is also double that of conventional drugs, and growth is expected to remain robust for the foreseeable future. As a result of their rapid growth, many new players are entering this market and most current manufacturers are expanding their manufacturing capacities. Moreover, with the anticipated launch of a number of biosimilar drugs in the next five years, we expect a significant expansion in the global biopharmaceutical manufacturing capacity. We expect these trends to make biopharmaceutical manufacturing a very lucrative opportunity for investors and manufacturers.

biopharmaceutical manufacturing market report

Category Overview

The global biopharmaceutical manufacturing has been categorized on the basis of cell culture which includes mammalian cell culture and microbial cell culture. Currently, the largest number of biopharmaceutical products are manufactured using mammalian cell culture. Moreover, the mammalian-cell based products are more compatible with patients as these have been shown to cause minimum adverse reactions. As a result, there has been an increase in the mammalian based products over the past several years. Currently, mammalian cell culture holds a dominating share accounting for 56% in the total biopharmaceutical cell culture market. On the other hand, a significant growth has been observed in the microbial based products as well. A strong growth in the sales of dominant drugs such as Humalog, Lantus, Neupogen, Neulasta, and Betaseron/Betaferon have sustained the growth of biopharmaceutical manufacturing market.

On the basis of class, the market has been segmented as follows: Monoclonal Antibodies, Recombinant Proteins, Interferon, Granulocyte Colony-Stimulating Factor (G-CSF), Erythropoietin, Human Growth Hormones, Recombinant Human Insulin, Purified Proteins and Vaccines. Currently, Monoclonal Antibodies represents the fastest growing segment in this market.

Regional Market Overview

Currently, North America accounts for the largest biomanufacturing capacity followed by Europe and Asia. Technological advancements and high healthcare spending are some of the major factors that are driving the growth of the North American market. On the other hand, driven by factors such as emerging markets, increasing trends of contract manufacturing and a large patient pool, Asia will represent the fastest growing market.

Competitive landscape

In the recent past, the in-house manufacturing has experienced a shift towards contract manufacturing due to large volume requirements, cost saving measures and lack of expertise in particular segments of biopharmaceuticals. Currently, the contract manufacturing organisations (CMOs) accounts for around one third of the global biopharmaceutical capacities. The report also covers an in-depth analysis of the key companies operating in the global biopharmaceutical manufacturing market such as Pfizer Inc., Roche, Amgen Inc. Novo Nordisk, AbbVie Inc, Sanofi S.A, Eli Lilly, Johnson & Johnson, Merck Co., etc


1 Preface
2 Research Methodology and Market Definitions
3 Executive Summary
4 Global Biopharmaceutical Market: Key Trends

    4.1 Biopharmaceuticals are Growing Faster than Small Molecule Drugs
    4.2 Growth of Biosimilars will Push Volumes and Introduce New Players in this Market
    4.3 A Rich Biopharmaceutical Pipeline will Drive the Capacity Demand in the Coming Years
    4.4 Increasing Trends in Mergers and Acquisitions will Increase Redundant Capacities
    4.5 Increasing Focus on Personalized Medicines and High Value Low Volume Markets
    4.6 Higher Titers will Reduce Capacity Demand
    4.7 Growth in the Use of Cost Effective Disposable Technologies
    4.8 Despite Sufficient Global Capacity, Its Uneven Distribution will Continue to Spur Demand
5 Global Biopharmaceutical Market: Industry Performance
    5.1 Current and Historical Sales Trends
    5.2 Market Breakup by Region
    5.3 Market Breakup by Expression Systems
    5.4 Market Breakup by Product Type
    5.5 Market Outlook
     5.6 SWOT Analysis
         5.6.1 Strengths
         5.6.2 Weaknesses
         5.6.3 Opportunities
         5.6.4 Threats
     5.7 Value Chain Analysis
     5.8 Porter’s Five Forces Analysis
         5.8.1 Overview
         5.8.2 Bargaining Power of Buyers
         5.8.3 Bargaining Power of Suppliers
         5.8.4 Degree of Competition
         5.8.5 Threat of New Entrants
         5.8.6 Threat of Substitutes
  6 Regional Biopharmaceutical Market Analysis
      6.1 United States
        6.1.1 Current and Historical Sales Trends
        6.1.2 Market Outlook
     6.2 Canada
        6.2.1 Current and Historical Sales Trends
        6.2.2 Market Outlook
    6.3 United Kingdom
        6.3.1 Current and Historical Sales Trends
        6.3.2 Market Outlook
    6.4 Germany
        6.4.1 Current and Historical Sales Trends
        6.4.2 Market Outlook
    6.5 France
        6.5.1 Current and Historical Sales Trends
        6.5.2 Market Outlook
    6.6 Italy
         6.6.1 Current and Historical Sales Trends
        6.6.2 Market Outlook
    6.7 Spain
        6.7.1 Current and Historical Sales Trends
        6.7.2 Market Outlook
    6.8 Russia
         6.8.1 Current and Historical Sales Trends
         6.8.2 Market Outlook
     6.9 Brazil
         6.9.1 Current and Historical Sales Trends
        6.9.2 Market Outlook
    6.10 Australia
        6.10.1 Current and Historical Sales Trends
        6.10.2 Market Outlook
7 Global Biopharmaceutical Manufacturing Industry
    7.1 Current and Historical Manufacturing Capacity Trends
    7.2 Market Breakup by Region
        7.2.1 North America
            7.2.1.1 Current and Historical Manufacturing Capacity Trends
            7.2.1.2 Market Outlook
        7.2.2 Europe
            7.2.2.1 Current and Historical Manufacturing Capacity Trends
            7.2.2.2 Market Outlook
        7.2.3 Asia
            7.2.3.1 Current and Historical Manufacturing Capacity Trends
            7.2.3.2 Market Outlook
    7.3 Market Breakup by Cell Culture
        7.3.1 Mammalian Cell Culture
            7.3.1.1 Key Market Drivers
            7.3.1.2 Current and Historical Sales Trends
            7.3.1.3 Current and Historical Manufacturing Capacity Trends
            7.3.1.4 Market Breakup by Region
            7.3.1.5 Market Breakup by Product Type
            7.3.1.6 Key Players
            7.3.1.7 Market Outlook
        7.3.2 Microbial Cell Culture
            7.3.2.1 Key Market Drivers
            7.3.2.2 Current and Historical Sales Trends
            7.3.2.3 Current and Historical Manufacturing Capacity Trends
            7.3.2.4 Market Breakup by Product
            7.3.2.5 Market Breakup by Region
            7.3.2.6 Key Players
            7.3.2.7 Market Outlook
    7.4 Market Breakup by Class
        7.4.1 Monoclonal Antibodies
            7.4.1.1 Current and Historical Sales Trends
            7.4.1.2 Market Outlook
        7.4.2 Recombinant Proteins
            7.4.2.1 Current and Historical Sales Trends
            7.4.2.2 Market Outlook
        7.4.3 Interferon
            7.4.3.1 Current and Historical Sales Trends
            7.4.3.2 Market Outlook
        7.4.4 Granulocyte Colony-Stimulating Factor (G-CSF)
            7.4.4.1 Current and Historical Sales Trends
            7.4.4.2 Market Outlook
        7.4.5 Erythropoietin
            7.4.5.1 Current and Historical Sales Trends
            7.4.5.2 Market Outlook
        7.4.6 Recombinant Human Insulin
            7.4.6.1 Current and Historical Sales Trends
            7.4.6.2 Market Outlook
        7.4.7 Vaccines
            7.4.7.1 Current and Historical Sales Trends
            7.4.7.2 Market Outlook
        7.4.8 Human Growth Hormones (HGH)
            7.4.8.1 Current and Historical Sales Trends
            7.4.8.2 Market Outlook
        7.5 Market Outlook
8 Competitive Landscape
    8.1 Market Breakup by Manufacturer Type
        8.1.1 Product Companies
        8.1.2 Contract Manufacturers
    8.2 Key Player Profiles
        8.2.1 Roche
            8.2.1.1 Company Overview
            8.2.1.2 Key Financials
        8.2.2 Amgen
            8.2.2.1 Company Overview
            8.2.2.2 Key Financials
        8.2.3 Novo Nordisk
            8.2.3.1 Company Overview
            8.2.3.2 Key Financials
        8.2.4 AbbVie
            8.2.4.1 Company Overview
            8.2.4.2 Key Financials
        8.2.5 Sanofi S.A
            8.2.5.1 Company Overview
            8.2.5.2 Key Financials
        8.2.6 Johnson & Johnson
            8.2.6.1 Company Overview
            8.2.6.2 Key Financials
        8.2.7 Pfizer
            8.2.7.1 Company Overview
            8.2.7.2 Key Financials
        8.2.8 Merck & Co.
            8.2.8.1 Company Overview
            8.2.8.2 Key Financials
        8.2.9 Lilly
            8.2.9.1 Company Overview
            8.2.9.2 Key Financials
        8.2.10 Biogen Idec
            8.2.10.1 Company Overview
            8.2.10.2 Key Financials          
 

List of Figures
Figure 4-1: Global: Companies Manufacturing or Developing Active Substances for Follow-on Biologics (in no’s)
Figure 4-2: Global: Biopharmaceutical Products: Distribution by Production Technology (in no’s)
Figure 4-3: Global: Biopharmaceuticals: Mergers and Acquisitions Transaction Value (in US$ Billion)
Figure 4-4: Global: Orphan Drug Market: Designated vs Approvals (in no’s), 2005-2016
Figure 4-5: Global: Personalized Medicine Market (in US$ Billion), 2009 and 2016
Figure 4-6: Increase in Titers and Reduction in Capacity Utilization Rate (in %), 2009 and 2016
Figure 4-7: Disposable (Single Use) vs Stainless Steel Bioreactors
Figure 4-8: United States and Western Europe: Capacity Expansion
Figure 5-1: Global: Biopharmaceutical Market: Sales Trend (in US$ Billion), 2009–2016
Figure 5-2: Global: Biopharmaceutical Market: Breakup by Region (in %), 2016
Figure 5-3: Global: Biopharmaceutical Market: Breakup by Various Expression Systems (in %), 2016
Figure 5-4: Global: Biopharmaceutical Market: Expression Systems (Respondents’ Trends), 2009–2016
Figure 5-5: Global: Biopharmaceutical Market: Breakup by Drug Sales (in %), 2016
Figure 5-6: Global: Biopharmaceutical: Sales Trend Forecast (in US$ Billion), 2017–2021
Figure 5-7: Global: Biopharmaceutical: SWOT Analysis
Figure 5-8: Global: Biopharmaceutical: Value Chain Analysis
Figure 5-9: Global: Biopharmaceutical: Porter’s Five Forces Analysis
Figure 6-1: United States: Biopharmaceutical Market: Sales Trend (in US$ Million), 2009 – 2016
Figure 6-2: United States: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2017 – 2021
Figure 6-3: Canada: Biopharmaceutical Market: Sales Trend (in US$ Million), 2009 – 2016
Figure 6-4: Canada: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2017–2021
Figure 6-5: United Kingdom: Biopharmaceutical Market: Sales Trend (in US$ Million), 2009-2016
Figure 6-6: United Kingdom: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2017–2021
Figure 6-7: Germany: Biopharmaceutical Market: Sales Trend (in US$ Million), 2009 – 2016
Figure 6-8: Germany: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2017 – 2021
Figure 6-9: France: Biopharmaceutical Market: Sales Trend (in Million US$), 2009 – 2016
Figure 6-10: France: Biopharmaceutical Market: Sales Trend Forecast (in Million US$), 2017 – 2021
Figure 6-11: Italy: Biopharmaceutical Market: Sales Trend (in US$ Million), 2009–2016
Figure 6-12: Italy: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2017–2021
Figure 6-13: Spain: Biopharmaceutical Market: Sales Trend (in US$ Million), 2009–2016
Figure 6-14: Spain: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2017–2021
Figure 6-15: Russia: Biopharmaceutical Market: Sales Trend (in US$ Million), 2009–2016
Figure 6-16: Russia: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2017–2021
Figure 6-17: Brazil: Biopharmaceutical Market: Sales Trend (in US$ Million), 2009–2016
Figure 6-18: Brazil: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2016-2021
Figure 6-19: Australia: Biopharmaceutical Market: Sales Trend (in US$ Million), 2009–2016
Figure 6-20: Australia: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2017–2021
Figure 7-1: Global: Biopharmaceutical Manufacturing: Capacity Trends (in Kilo Liters), 2009-2016
Figure 7-2: Global: Biopharmaceuticals Manufacturing: Capacity Breakup by Region (in %), 2016
Figure 7-3: North America: Biopharmaceuticals Manufacturing: Capacity Trend (in Kilo Liters), 2009-2016
Figure 7-4: North America: Biopharmaceuticals Manufacturing: Capacity Trend Forecast (in Kilo Liters), 2017-2021
Figure 7-5: Europe: Biopharmaceuticals Manufacturing: Capacity Trend (in Kilo Liters), 2009-2016
Figure 7-6: Europe: Biopharmaceuticals Manufacturing: Capacity Trend Forecast (in Kilo Liters), 2017-2021
Figure 7-7: Asia: Biopharmaceuticals Manufacturing: Capacity Trend (in Kilo Liters), 2009-2016
Figure 7-8: Asia: Biopharmaceuticals Manufacturing: Capacity Trend Forecast (in Kilo Liters), 2017-2021
Figure 7-9: Global: Mammalian Products: Sales Trend (in US$ Billion), 2009-2016
Figure 7-10: Global: Mammalian Cell Culture: Capacity Trend (in Kilo Liters), 2009-2016
Figure 7-11: Global: Mammalian Cell Culture: Capacity Utilization Trend (in %), 2009-2016
Figure 7-12: Global: Mammalian Cell Culture: Capacity Trends by Region (in Kilo Liters), 2009-2016
Figure 7-13: Global: Mammalian Cell Culture: Demand Breakup of Commercial Antibody Products (in %), 2016
Figure 7-14: Global: Mammalian Cell Culture: Market Breakup by Key Players (in %), 2016
Figure 7-15: Global: Mammalian Products: Sales Trend Forecast (in US$ Billion), 2017 – 2021
Figure 7-16: Global: Mammalian Cell Culture: Capacity Trend Forecast (in Kilo Liters), 2017–2021
Figure 7-17: Global: Mammalian Cell Culture: Capacity Trends Forecast by Region (in Kilo Liters), 2017-2021
Figure 7-18: Global: Microbial Products: Sales Trend (in US$ Billion), 2009-2016
Figure 7-19: Global: Microbial Cell Culture: Capacity Trend (in Kilo Liters), 2009-2016
Figure 7-20: Global: Microbial Cell Culture: Capacity (Commercial Volume) Trend (in Kilo Liters), 2009-2016
Figure 7-21: Global: Microbial Cell Culture: Capacity (Clinical Volume) Trend (in Kilo Liters), 2009-2016
Figure 7-22: Global: Microbial Cell Culture: Capacity Utilization Trend (in %), 2009-2016
Figure 7-23: Global: Microbial Cell Culture: Demand Breakup of Commercial Products (in %), 2016
Figure 7-24: Global: Microbial Cell Culture: Capacity (Commercial Volume) Trends by Region (in Kilo Liters), 2009-2016
Figure 7-25: Global: Microbial Cell Culture: Capacity (Clinical Volume) Trends by Region (in Kilo Liters), 2009-2016
Figure 7-26: Global: Microbial Cell Culture: Market Breakup by Key Players (in %), 2016
Figure 7-27: Global: Microbial Products: Sales Trend Forecast (in US$ Billion), 2017– 2021
Figure 7-28: Global: Microbial Products: Capacity Trend Forecast (in Kilo Liters), 2017–2021
Figure 7-29: Global: Microbial Cell Culture: Capacity (Commercial Volume) Trends Forecast by Region (in Kilo Liters), 2017–2021
Figure 7-30: Global: Microbial Cell Culture: Capacity (Clinical Volume) Trends Forecast by Region (in Kilo Liters), 2017–2021
Figure 7-31: Global: Monoclonal Antibodies: Sales Trend (in US$ Billion), 2009-2016
Figure 7-32: Global: Monoclonal Antibodies: Sales Trend (in US$ Billion), 2017-2021
Figure 7-33: Global: Recombinant Proteins: Sales Trend (in US$ Billion), 2009-2016
Figure 7-34: Global: Recombinant Proteins: Sales Trend Forecast (in US$ Billion), 2017-2021
Figure 7-35: Global: Interferon: Sales Trend (in US$ Billion), 2009-2016
Figure 7-36: Global: Interferon: Sales Trend Forecast (in US$ Billion), 2017-2021
Figure 7-37: Global: Granulocyte Colony-Stimulating Factor (G-CSF): Sales Trend (in US$ Billion), 2009-2016
Figure 7-38: Global: Granulocyte Colony-Stimulating Factor (G-CSF): Sales Trend Forecast (in US$ Billion), 2017-2021
Figure 7-39: Global: Erythropoietin: Sales Trend (in US$ Billion), 2009-2016
Figure 7-40: Global: Erythropoietin: Sales Trend Forecast (in US$ Billion), 2017-2021
Figure 7-41: Global: Recombinant Human Insulin: Sales Trend (in US$ Billion), 2009-2016
Figure 7-42: Global: Recombinant Human Insulin: Sales Trend Forecast (in US$ Billion), 2017-2021
Figure 7-43: Global: Vaccines: Sales Trend (in US$ Billion), 2009-2016
Figure 7-44: Global: Vaccines: Sales Trend Forecast (in US$ Billion), 2017-2021
Figure 7-45: Global: Human Growth Hormones (HGH): Sales Trend (in US$ Billion), 2009-2016
Figure 7-46: Global: Human Growth Hormones (HGH): Sales Trend Forecast (in US$ Billion), 2017-2021
Figure 7-47: Global: Biopharmaceutical Manufacturing: Capacity Trend Forecast (In Kilo Liters), 2017-2021
Figure 8-1: Global: Biopharmaceutical Manufacturing: Capacity Breakup by Manufacturer Type (in %), 2016
Figure 8-2: Global: Biopharmaceutical Manufacturing: Capacity Breakup Forecast by Manufacturer Type (in %), 2021
Figure 8-3: Global: Biopharmaceutical Product Companies: Capacity Trend (in Kilo Liters), 2009–2016
Figure 8-4: Global: Biopharmaceutical Product Companies: Capacity Trend Forecast (in Kilo Liters), 2017–2021
Figure 8-5: Global: Biopharmaceutical CMOs: Capacity Trend (in Kilo Liters), 2009-2016
Figure 8-6: Global: Biopharmaceutical CMOs: Capacity Trend Forecast (in Kilo Liters), 2017- 2021
Figure 8-7: Roche: Sales Value Trend (in Billion US$), 2011-2016
Figure 8-8: Roche: Revenue Breakup by Region (in %), 2016
Figure 8-9: Amgen: Sales Value Trend (in Billion USD), 2011-2016
Figure 8-10: Amgen: Revenue Breakup by Region (in %), 2016
Figure 8-11: Novo Nordisk: Sales Value Trend (in Billion USD), 2011-2016
Figure 8-12: Novo Nordisk: Revenue Breakup by Region (in %), 2016
Figure 8-13: AbbVie: Sales Value Trend (in Billion USD), 2011-2016
Figure 8-14: AbbVie: Revenue Breakup by Region (in %), 2016
Figure 8-15: Sanofi S.A: Sales Value Trend (in Billion USD), 2011-2016
Figure 8-16: Sanofi S.A: Revenue Breakup by Region (in %), 2016
Figure 8-17: Johnson & Johnson: Sales Value Trend (in Billion USD), 2011-2016
Figure 8-18: Johnson & Johnson: Revenue Breakup by Region (in %), 2016
Figure 8-19: Pfizer: Sales Value Trend (in Billion USD), 2011-2016
Figure 8-20: Pfizer: Revenue Breakup by Region (in %), 2016
Figure 8-21: Merck & Co: Sales Value Trend (in Billion USD), 2011-2016
Figure 8-22: Merck & Co: Revenue Breakup by Region (in %), 2016
Figure 8-23: Lilly: Sales Value Trend (in Billion USD), 2011-2016
Figure 8-24: Lilly: Revenue Breakup by Region (in %), 2016
Figure 8-25: Biogen Idec: Sales Value Trend (in Billion USD), 2011-2016
Figure 8-26: Biogen Idec: Revenue Breakup by Region (in %), 2016
 
 

List of Tables

Table 4-1: Global: Small Molecule Sales vs. Biopharmaceutical Sales (in Billion US$), 2009-2016
Table 8-1: Roche: Financial Data (2011-2016)
Table 8-2: Amgen: Financial Data (2011-2016)
Table 8-3: Novo Nordisk: Financial Data (2011-2016)
Table 8-4: AbbVie: Financial Data (2011-2016)
Table 8-5: Sanofi S.A: Financial Data (2011-2016)
Table 8-6: Johnson & Johnson: Financial Data (2011-2016)
Table 8-7: Pfizer: Financial Data (2011-2016)
Table 8-8: Merck & Co: Financial Data (2011-2016)
Table 8-9: Lilly: Financial Data (2011-2016)
Table 8-10: Biogen Idec: Financial Data (2011-2016)


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Special Prices


    IMARC provides special pricing for:

  • Academic Institutes
  • Government Agencies
  • Nonprofit Organizations
  • For more information, feel free to contact us.






Related Report

GCC Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022

According to IMARC Group’s latest report titled “GCC Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022”, the generic drugs market in the GCC reached a value of nearly US$ 1,550 Million in 2016, exhibiting a CAGR of 15% during 2009-2016.


US Generic Injectables Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022

According to IMARC Group’s new report titled “US Generic Injectables Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022”, the US generic injectables market reached a value of US$ 10 Billion in 2016, exhibiting a CAGR of more than 9% during 2009-2016.


Generic Injectables Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022

According to IMARC Group’s latest report titled, “Generic Injectables Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022”, the global generic injectables market reached a value of more than US$ 23 Billion in 2016, exhibiting a CAGR of around 9% during 2009-...


Global Biopharmaceutical Market Report & Forecast (2017-2021)

IMARC’s new report “Global Biopharmaceutical Market Report & Forecast (2017-2021)” gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market tre...


Global Portable Medical and Healthcare Devices Market Report (Cardiac Monitoring Devices, Blood Glucose Monitoring, Pulse Oximetry Devices, Wearable BP Monitors, Smart Wrist-Wearables, Smart Garments etc.) (2017-2021)

The health of a citizen directly affects the productivity and growth of a country’s economy. Therefore, the expenditure on maintaining a good health becomes indispensable. A study has revealed a considerable increment in the heart related problems worldwide which often requires treatment paired wi...